Evidence map›Paper›PMID 40852760›Full record

Trial reportHead & neck2026

Safety and Efficacy Findings From a Phase Ib/II Study of ASP-1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.

David M Cognetti, Joseph M Curry, Jennifer Johnson, Michael Kwon, Shirley Y Su, Francisco Civantos, Coral Olazagasti, Joseph Valentino, Susanne M Arnold, R Bryan Bell and 8 more

Abstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

David M CognettiDepartment of Otolaryngology - Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Joseph M CurryDepartment of Otolaryngology - Head and Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Jennifer JohnsonSidney Kimmel Comprehensive Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Michael KwonDepartment of Diagnostic Radiology, Division of Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shirley Y SuDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Francisco CivantosDepartment of Otolaryngology - Head and Neck Surgery, Miller School of Medicine, University of Miami, Miami, Florida, USA.
Coral OlazagastiMedical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, USA.
Joseph ValentinoDepartment of Otolaryngology - Head and Neck Surgery, University of Kentucky, Lexington, Kentucky, USA.
Susanne M ArnoldDivision of Medical Oncology, University of Kentucky, Lexington, Kentucky, USA.
R Bryan BellDivision of Surgical Oncology, Radiation Oncology, and Clinical Programs, Providence Cancer Institute, Portland, Oregon, USA.
Michael K GibsonDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kyle MannionDepartment of Otolaryngology - Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kathryn M Van AbelDepartment of Otolaryngology - Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Katharine A PriceDepartment of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Haiying DongGlobal Data and Analytics, Rakuten Medical, Inc, San Diego, California, USA.
Amy H ThornePre-Clinical Research and Development, Rakuten Medical, Inc, San Diego, California, USA.
Toshiaki SuzukiRakuten Medical, Inc, San Diego, California, USA.
Ann M GillenwaterDepartment of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
NCI NIH HHS P30 CA177558Rakuten Medical
6 · The paper itself

Abstract

backgroundASP-1929 photoimmunotherapy-cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation-results in rapid, selective cell killing.

methodsThis phase Ib/II open-label study evaluated ASP-1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD-L1 combined positive score ≥ 1, ineligible for standard locoregional therapy). Primary objectives were safety/tolerability and objective response rate (ORR). Secondary objectives included overall survival (OS) and progression-free survival (PFS).

resultsEighteen patients (median age 63 years, 74% male) comprised the photoimmunotherapy-evaluable population. The confirmed ORR was 27.8% (95% CI 9.7-53.5); four of five responders had complete responses (95% CI, 6.4-47.6). Median OS was 25.6 months (95% CI, 14.6-not evaluable); median PFS was 2.9 months (95% CI, 1.4-14.6). The most common serious adverse reactions were dysphagia and tongue edema (each n = 2; 10.5%).

conclusionsASP-1929 photoimmunotherapy plus pembrolizumab was generally tolerable, with promising efficacy in patients with recurrent/metastatic HNSCC.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCetuximabHead and Neck NeoplasmsImmunotherapyNeoplasm Recurrence, LocalPhototherapySquamous Cell Carcinoma of Head and NeckAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCetuximabpembrolizumabadvanced diseaseASP‐1929 photoimmunotherapybiomarker analysisHNSCCpembrolizumab

Identifiers

PMID40852760
PMCPMC12703558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.